Brainstorm Cell Therapeutics Ownership | Who Owns Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics Ownership Summary

Brainstorm Cell Therapeutics is owned by 3.72% institutional investors, 11.92% insiders, and 84.36% retail investors. Blackrock is the largest institutional shareholder, holding 0.60% of BCLI shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 1.33% of its assets in Brainstorm Cell Therapeutics shares.

BCLI Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Brainstorm Cell Therapeutics	3.72%	11.92%	84.36%
Sector	Healthcare Stocks	487.91%	11.08%	-398.99%
Industry	Biotech Stocks	307.10%	11.11%	-218.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Blackrock	386.41K	0.60%	$130.80K
Blackrock funding, inc. /de	25.17K	0.40%	$28.19K
Weaver consulting group	15.62K	0.25%	$17.50K
Northern trust	112.36K	0.17%	$38.03K
Raymond james & associates	111.28K	0.17%	$37.67K
Raymond james financial	5.16K	0.08%	$5.78K
Virtu financial	49.59K	0.08%	$17.00K
Morgan stanley	36.98K	0.06%	$12.52K
Harbour investments	3.56K	0.06%	$3.99K
Lpl financial	10.05K	0.02%	$3.40K

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Weaver consulting group	15.62K	0.00%	$17.50K
Virtu financial	49.59K	0.00%	$17.00K
Institutional & family asset management	6.00K	0.00%	$2.03K
Harbour investments	3.56K	0.00%	$3.99K
Bogart wealth	-	-	-
Gsa capital partners llp	-	-	-
Geode capital management	-	-	-
Tower research capital llc (trc)	-	-	-
St germain d j	33.00	-	$23.00
Nelson, van denburg & campbell wealth management group	-	-	-

Top Buyers

Holder	Shares	% Assets	Change
Northern trust	112.36K	-	57.57K
Virtu financial	49.59K	0.00%	49.59K
Lpl financial	10.05K	-	10.05K
Citadel advisors	7.20K	-	6.40K
Raymond james financial	5.16K	-	5.16K

Top Sellers

Holder	Shares	% Assets	Change
Vanguard group	-	-	-1.51M
Armistice capital	-	-	-690.67K
Geode capital management	-	-	-682.82K
Abner herrman & brock	-	-	-145.50K
State street	-	-	-117.26K

New Positions

Holder	Shares	% Assets	Change	Value
Lpl financial	10.05K	-	10.05K	$3.40K
Raymond james financial	5.16K	-	5.16K	$5.78K
Harbour investments	3.56K	0.00%	3.56K	$3.99K

Sold Out

Holder	Change
Bogart wealth	-2.00
Corecap advisors	-8.00
Westside investment management	-12.00
Cranbrook wealth management	-66.00
Mark sheptoff financial planning	-100.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2025	33	6.45%	235,908	-72.76%	3	1.40%	11	-8.33%	3	-
Mar 31, 2025	31	-3.13%	866,078	238.80%	16	70.37%	12	-29.41%	3	-78.57%
Dec 31, 2024	4	-89.19%	48,928	-99.55%	-	0.40%	1	-90.00%	2	-77.78%
Sep 30, 2024	37	-26.00%	10,822,353	-10.37%	15	4.37%	10	-52.38%	9	-
Jun 30, 2024	50	4.17%	12,075,121	210.89%	18	51.82%	21	75.00%	9	-18.18%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard US Total Market Shares ETF	1.06M	1.33%	-2.00
Vanguard Total Stock Mkt Idx Inv	22.14K	0.39%	-28.58K
Fidelity Extended Market Index	31.41K	0.32%	-
Vanguard Institutional Extnd Mkt Idx Tr	26.73K	0.27%	-
Fidelity Total Market Index	9.56K	0.10%	-
Fidelity Series Total Market Index	7.98K	0.08%	-
BlackRock Extended Equity Market K	62.75K	0.08%	-27.00
Northern Trust Extended Eq Market Idx	5.32K	0.05%	-
NT Ext Equity Mkt Idx Fd - L	5.32K	0.05%	-
Spartan Extended Market Index Pool E	3.28K	0.05%	239.00

Recent Insider Transactions

Date	Name	Role	Activity	Value
Oct 01, 2024	Lebovits Chaim	President & CEO	Buy	$6.29K
Sep 30, 2024	Lebovits Chaim	President & CEO	Buy	$5.02K
May 28, 2024	Lebovits Chaim	President & CEO	Buy	$7.77K
May 21, 2024	Lebovits Chaim	President & CEO	Buy	$14.47K
May 22, 2024	Lebovits Chaim	President & CEO	Buy	$16.00K

Insider Transactions Trends

Date	Buy	Sell
2025 Q1	-	-
2024 Q4	1	-
2024 Q3	1	1
2024 Q2	11	-
2024 Q1	-	-

BCLI Ownership FAQ

Who Owns Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics shareholders are primarily institutional investors at 3.72%, followed by 11.92% insiders and 84.36% retail investors. The average institutional ownership in Brainstorm Cell Therapeutics's industry, Biotech Stocks , is 307.10%, which Brainstorm Cell Therapeutics falls below.

Who owns the most shares of Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics’s largest shareholders are Blackrock (386.41K shares, 0.60%), Blackrock funding, inc. /de (25.17K shares, 0.40%), and Weaver consulting group (15.62K shares, 0.25%). Together, they hold 1.24% of Brainstorm Cell Therapeutics’s total shares outstanding.

Does Blackrock own Brainstorm Cell Therapeutics?

Yes, BlackRock owns 0.60% of Brainstorm Cell Therapeutics, totaling 386.41K shares as of Jun 2024. This represents 0% of BlackRock's total assets, with a market value of 130.8K$. In the last quarter, BlackRock decreased its holdings by -103K shares, a -21.03% change.

Who is Brainstorm Cell Therapeutics’s biggest shareholder by percentage of total assets invested?

Weaver consulting group is Brainstorm Cell Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.00% of its assets in 15.62K Brainstorm Cell Therapeutics shares, valued at 17.5K$.

Who is the top mutual fund holder of Brainstorm Cell Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Brainstorm Cell Therapeutics shares, with 1.33% of its total shares outstanding invested in 1.06M Brainstorm Cell Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools